Crispr Therapeutics Stock News

CRISPR Therapeutics (NASDAQ: CRSP ) has outperformed the market over the past 5 years by 12.95% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have purchased 47.08 shares of CRISPR Therapeutics at the time with $1,000. This investment in CRSP … Full story available on Benzinga.com

CRISPR Therapeutics AG (NASDAQ:CRSP) traded at $60.04 at close of the session on Tuesday, 03/15/22, made an upward move of 3.41% on its previous day’s price. Looking at the stock we see that its previous close was $58.06 and the beta (5Y monthly) reads 2.08 with the day’s price range being $57.78 – $60.77. The … CRISPR Therapeutics AG (NASDAQ: CRSP) Is A Buzzing Hot Stock Read More »

It's been a tough past 12 months for this gene-editing specialist.

They're all successful drugmakers with solid growth prospects.

The biotech stock is making gains despite market pressures, but it's still down roughly 71% from its high.

The biotech stock is making gains despite market pressures, but it''s still down roughly 71% from its high.

Gainers: CRISPR Therapeutics AG (CRSP) +26%. Micron Technology, Inc

The biotech stock is making gains despite market pressures, but it's still down roughly 71% from its high.

Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.

These most-shorted stocks have investors seeing red, but there is a silver lining that's playing out on the price chart for today's buyers. The post 3 Ark Invest Most-Shorted Stocks to Buy appeared fi

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $62.43, marking a +0.02% move from the previous day.

In the last trading session, 2.58 million shares of the CRISPR Therapeutics AG (NASDAQ:CRSP) were traded, and its beta was 2.03. Most recently the company’s share price was $60.35, and it changed around $5.15 or 9.33% from the last close, which brings the market valuation of the company to $4.74B. CRSP currently trades at a … Why CRISPR Therapeutics AG (NASDAQ: CRSP) Stock Should Not Be Taken For Granted By Investors In 2022 Read More »

Don't buy Cathie Wood stocks because the market was singing on Wednesday, purchase them because of a much bigger and bullish picture. The post 3 Cathie Wood Stocks to Buy appeared first on InvestorPla

Recent comments from the company's CEO are prompting bullish momentum for the stock.

ZUG, Switzerland and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for